Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05710406 | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | active not recruiting | Phase 2 / Phase 3 | 1 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05724563 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | active not recruiting | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 2, 2026 |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07680088 | Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer | not yet recruiting | Phase 2 | 17 | University of Texas Southwestern Medical CenterOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT07682376 | Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 96 | Harbin Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07682454 | Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | not yet recruiting | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04098081 | 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma | active not recruiting | Phase 2 | 15 | University of Maryland, BaltimoreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | University of California, IrvineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04643366 | Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer | recruiting | Phase 2 | 64 | Virginia Commonwealth UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05836584 | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | active not recruiting | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06364384 | Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma | recruiting | Phase 2 | 20 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07139951 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence | enrolling by invitation | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07595874 | Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3(NEST3) | recruiting | Phase 2 | 100 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678580 | Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 50 | Tang-Du HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03051464 | Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery(MORPHEUS) | recruiting | Phase 2 / Phase 3 | 131 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 2 | Jun 30, 2026 | clinicaltrials |
| NCT06015724 | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer(DARANIVOVAX) | active not recruiting | Phase 2 | 19 | Georgetown UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07056777 | Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer | recruiting | Phase 1 / Phase 2 | 186 | Zhejiang Doer Biologics Co., Ltd.INDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02945566 | Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?(STAR-TREC) | active not recruiting | Phase 2 / Phase 3 | 380 | University of BirminghamOTHER | 5 | Jun 29, 2026 | clinicaltrials |
| NCT05516628 | Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma(EMPHASIS) | recruiting | Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT06780787 | FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06922383 | A Clinical Study of Arfolitixorin in Patients With mCRC | recruiting | Phase 1 / Phase 2 | 90 | Isofol Medical ABINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06412198 | A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | recruiting | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07042919 | Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 59 | Devalingam MahalingamOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07656766 | Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 32 | Peking University People's HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669220 | A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)(STAR) | recruiting | Phase 2 | 76 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669740 | A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05426005 | Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03991832 | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors(SOLID) | active not recruiting | Phase 2 | 58 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04929392 | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer | active not recruiting | Phase 2 | 3 | City of Hope Medical CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05929885 | Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients | recruiting | Phase 2 | 50 | National Cancer Centre, SingaporeOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06038578 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | recruiting | Phase 2 | 146 | Toray Industries, IncINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT06783140 | Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer(PLATINUM-CAN) | active not recruiting | Phase 2 / Phase 3 | 10 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07662031 | Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 25 | Washington University School of MedicineOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02151084 | A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | active not recruiting | Phase 2 | 57 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04727307 | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial(AB-LATE02) | active not recruiting | Phase 2 | 202 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05843188 | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 155 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07255664 | A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC(ProbeTILity) | recruiting | Phase 1 / Phase 2 | 12 | CuraCell TX ABINDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658872 | Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | not yet recruiting | Phase 2 | 120 | Sichuan UniversityOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT06381154 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 24 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07339488 | Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma(ILDR-03) | recruiting | Phase 2 | 43 | Chuangzhen ChenOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655661 | Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 52 | Ming LiuOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656376 | Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation | not yet recruiting | Phase 2 / Phase 3 | 465 | Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2026source: clinicaltrials